| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CYCT |
| Uniprot No | P00015 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-105aa |
| 氨基酸序列 | MGDAEAGKKIFVQKCAQCHTVEKGGKHKTGPNLWGLFGRKTGQAPGFSYTDANKNKGVIWSEETLMEYLENPKKYIPGTKMIFAGIKKKSEREDLIKYLKQATSS |
| 预测分子量 | 11.7kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CYCT(Cyclin T)重组蛋白的3篇参考文献概览，涵盖制备、功能及应用研究方向：
1. **《重组人Cyclin T1蛋白的表达纯化及其与HIV-1 Tat相互作用研究》**
- 作者：Smith, J. et al.
- 摘要：研究通过大肠杆菌系统成功表达并纯化重组人Cyclin T1蛋白，验证其与HIV-1 Tat蛋白的特异性结合，为抗病毒药物筛选提供实验基础。
2. **《Cyclin T2/CDK9复合体的重组表达与激酶活性分析》**
- 作者：Li, X. & Wang, Y.
- 摘要：利用昆虫细胞系统共表达Cyclin T2与CDK9.纯化获得功能性复合体，证实其在体外磷酸化RNA聚合酶Ⅱ羧基末端结构域(CTD)的活性。
3. **《Cyclin T1结构域解析：基于重组蛋白的晶体学研究》**
- 作者：Zhang, R. et al.
- 摘要：通过X射线晶体学解析重组Cyclin T1蛋白的三维结构，鉴定其与CDK9及Tat蛋白结合的关键功能域，为靶向分子设计提供结构依据。
*注：以上文献为示例性概括，具体研究需以实际发表内容为准。*
CYCT, commonly referred to as Cyclin T, is a critical regulatory protein involved in cell cycle progression and transcriptional elongation. As a member of the cyclin family, it forms a functional complex with cyclin-dependent kinase 9 (CDK9), collectively known as the positive transcription elongation factor b (P-TEFb). This complex plays a pivotal role in releasing RNA polymerase II (Pol II) from promoter-proximal pausing, enabling transcriptional elongation of many cellular and viral genes, including HIV-1. The CYCT-CDK9 interaction is essential for the replication of HIV-1. as the viral Tat protein recruits P-TEFb to the transactivation response (TAR) element of viral RNA to enhance viral gene expression.
Structurally, CYCT contains conserved cyclin domains that mediate CDK9 binding and activation. Alternative splicing generates isoforms like Cyclin T1 and T2. with T1 being the primary partner for CDK9 in humans. Dysregulation of CYCT has been implicated in cancers, neurodegenerative diseases, and viral pathogenesis, making it a therapeutic target. For instance, inhibiting the CYCT-CDK9 interaction disrupts HIV replication, while its overexpression in certain cancers correlates with poor prognosis due to enhanced cell proliferation.
Recombinant CYCT proteins are typically produced in bacterial (e.g., *E. coli*) or mammalian expression systems, ensuring proper folding and post-translational modifications. These proteins are widely used in biochemical assays, structural studies, and drug discovery to elucidate P-TEFb mechanisms or screen inhibitors. Additionally, recombinant CYCT serves as a tool to study transcriptional regulation, host-pathogen interactions, and epigenetic modifications. Its versatility in research underscores its significance in both basic science and translational applications, including antiviral therapies and cancer treatment strategies.
×
